Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Oct 13;29(20):4021-4023.
doi: 10.1158/1078-0432.CCR-23-1954.

Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer

Giovanni Randon  1 , Filippo Pietrantonio  1
Affiliations
Editorial

Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer

Giovanni Randon et al. Clin Cancer Res. .

Abstract

Overexpression of the EGFR ligands amphiregulin (AREG)/epiregulin (EREG) may be a surrogate of EGFR dependency regardless of sidedness in metastatic colorectal cancer. High AREG/EREG may be coupled with negative hyper-selection (i.e., lack of genomic drivers of primary resistance beyond RAS and BRAF) to identify patients with right-sided tumors and potential sensitivity to EGFR blockade. See related article by Williams et al., p. 4153.

PubMed Disclaimer

Figures

Figure 1. Graphical representation of the mechanisms of EGFR dependency in colorectal cancer. (Adapted from an image created with BioRender.com.)
Figure 1.
Graphical representation of the mechanisms of EGFR dependency in colorectal cancer. (Adapted from an image created with BioRender.com.)
See this image and copyright information in PMC

Comment on

  • Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer.
    Williams CJM, Elliott F, Sapanara N, Aghaei F, Zhang L, Muranyi A, Yan D, Bai I, Zhao Z, Shires M, Wood HM, Richman SD, Hemmings G, Hale M, Bottomley D, Galvin L, Cartlidge C, Dance S, Bacon CM, Mansfield L, Young-Zvandasara K, Sudan A, Lambert K, Bibby I, Coupland SE, Montazeri A, Kipling N, Hughes K, Cross SS, Dewdney A, Pheasey L, Leng C, Gochera T, Mangham DC, Saunders M, Pritchard M, Stott H, Mukherjee A, Ilyas M, Silverman R, Hyland G, Sculthorpe D, Thornton K, Gould I, O'Callaghan A, Brown N, Turnbull S, Shaw L, Seymour MT, West NP, Seligmann JF, Singh S, Shanmugam K, Quirke P. Williams CJM, et al. Clin Cancer Res. 2023 Oct 13;29(20):4153-4165. doi: 10.1158/1078-0432.CCR-23-0859. Clin Cancer Res. 2023. PMID: 37363997 Free PMC article.

References

    1. Williams CJM, Elliott F, Sapanara N, Aghaei F, Zhang L, Muranyi A, et al. . Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer. Clin Cancer Res 2023;29:4153–65. - PMC - PubMed
    1. Randon G, Yaeger R, Hechtman JF, Manca P, Fucà G, Walch H, et al. . EGFR amplification in metastatic colorectal cancer. J Natl Cancer Inst 2021;113:1561–9. - PMC - PubMed
    1. Jonker DJ, Karapetis CS, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, et al. . Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. Br J Cancer 2014;110:648–55. - PMC - PubMed
    1. Seligmann JF, Elliott F, Richman SD, Jacobs B, Hemmings G, Brown S, et al. . Combined epiregulin and amphiregulin expression levels as a predictive biomarker for panitumumab therapy benefit or lack of benefit in patients with RAS wild-type advanced colorectal cancer. JAMA Oncol 2016;2:633–42. - PubMed
    1. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Kaiser F, Al-Batran S-E, et al. . FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomized clinical trial. Br J Cancer 2021;124:587–94. - PMC - PubMed